Alentis ´Shares Their Colors´ for Rare Disease Day 2024 Post published:February 29, 2024 Continue ReadingAlentis ´Shares Their Colors´ for Rare Disease Day 2024
William Pao Joins Alentis Therapeutics as Independent Board Member Post published:January 8, 2024 Continue ReadingWilliam Pao Joins Alentis Therapeutics as Independent Board Member
Alentis Therapeutics Expands Leadership Team with the Appointment of Rizwan Velji as Chief Business Officer Post published:December 6, 2023 Continue ReadingAlentis Therapeutics Expands Leadership Team with the Appointment of Rizwan Velji as Chief Business Officer
Alentis Therapeutics Doses First ANCA-Associated Vasculitis Rapidly Progressive Glomerulonephritis Patient in Phase 2 Clinical Trial of Lixudebart (ALE.F02) Post published:December 5, 2023 Continue ReadingAlentis Therapeutics Doses First ANCA-Associated Vasculitis Rapidly Progressive Glomerulonephritis Patient in Phase 2 Clinical Trial of Lixudebart (ALE.F02)
Alentis Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of ALE.C04 in Head and Neck Squamous Cell Carcinoma (HNSCC) Post published:November 16, 2023 Continue ReadingAlentis Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of ALE.C04 in Head and Neck Squamous Cell Carcinoma (HNSCC)
Alentis Therapeutics to Participate in Multiple Business Conferences in November Post published:November 2, 2023 Continue ReadingAlentis Therapeutics to Participate in Multiple Business Conferences in November
Alentis Therapeutics to Present during the American Society of Nephrology Kidney Week Post published:October 26, 2023 Continue ReadingAlentis Therapeutics to Present during the American Society of Nephrology Kidney Week
Alentis Therapeutics Appoints Lung Experts Professors Tony Mok and Steven Nathan to its Scientific Advisory Board Post published:October 5, 2023 Continue ReadingAlentis Therapeutics Appoints Lung Experts Professors Tony Mok and Steven Nathan to its Scientific Advisory Board
Alentis Therapeutics to Sponsor the 2023 European Vasculitis Society Training Course Post published:September 20, 2023 Continue ReadingAlentis Therapeutics to Sponsor the 2023 European Vasculitis Society Training Course
Alentis Therapeutics to Present at Two Upcoming Investor Conferences Post published:September 6, 2023 Continue ReadingAlentis Therapeutics to Present at Two Upcoming Investor Conferences
